Johnson&Johnson Innovative Medicine, the pharmaceutical arm of J&J, is focused on developing breakthrough treatments for complex diseases like cancer, immunology issues, neurological disorders, and heart/lung conditions. By using cutting-edge science, data, and patient insights to create personalized medicines, J&J Innovative Medicine aims to prevent, treat, and cure serious illnesses and improve global health.
Role in the project
Johnson&Johnson Innovative Medicine (J&J IM) is one of the industry partners officially signatory to the BRIDGE project. J&J IM is actively contributing to the project with a particular focus on WP1 (“Regulatory Sandboxes: state-of-the-art, emerging trends and fitness criteria”), WP3 (“Regulatory Sandbox end-to-end simulation and validation”) and WP4 (“Sandbox recommendations for end-to-end operations, acceptance and sustainability”). J&J IM is also co-leading WP1, as well as one particular task (Task 1.3: “Development of regulatory sandbox readiness criteria”).